NANOBIOTIX SA - ADR (NBTX) Fundamental Analysis & Valuation
NASDAQ:NBTX • US63009J1079
Current stock price
35.12 USD
+0.5 (+1.44%)
Last:
This NBTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. NBTX Profitability Analysis
1.1 Basic Checks
- In the past year NBTX has reported negative net income.
- NBTX had a negative operating cash flow in the past year.
- In the past 5 years NBTX always reported negative net income.
- In the past 5 years NBTX always reported negative operating cash flow.
1.2 Ratios
- With a Return On Assets value of -35.36%, NBTX perfoms like the industry average, outperforming 58.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.36% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-59.57%
ROA(5y)-64.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for NBTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. NBTX Health Analysis
2.1 Basic Checks
- NBTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
- NBTX has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, NBTX has more shares outstanding
- The debt/assets ratio for NBTX is higher compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of -4.01, we must say that NBTX is in the distress zone and has some risk of bankruptcy.
- NBTX has a Altman-Z score (-4.01) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.01 |
ROIC/WACCN/A
WACC7.87%
2.3 Liquidity
- A Current Ratio of 1.09 indicates that NBTX should not have too much problems paying its short term obligations.
- NBTX has a Current ratio of 1.09. This is amonst the worse of the industry: NBTX underperforms 86.60% of its industry peers.
- A Quick Ratio of 1.09 indicates that NBTX should not have too much problems paying its short term obligations.
- NBTX has a Quick ratio of 1.09. This is amonst the worse of the industry: NBTX underperforms 85.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.09 | ||
| Quick Ratio | 1.09 |
3. NBTX Growth Analysis
3.1 Past
- NBTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 65.28%, which is quite impressive.
- The Revenue has grown by 167.56% in the past year. This is a very strong growth!
- The Revenue has been growing by 174.85% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)65.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.2%
Revenue 1Y (TTM)167.56%
Revenue growth 3YN/A
Revenue growth 5Y174.85%
Sales Q2Q%136.13%
3.2 Future
- NBTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 45.91% yearly.
- NBTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.97% yearly.
EPS Next Y-24.95%
EPS Next 2Y5.24%
EPS Next 3Y25.56%
EPS Next 5Y45.91%
Revenue Next Year9.99%
Revenue Next 2Y4.85%
Revenue Next 3Y37.36%
Revenue Next 5Y22.97%
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. NBTX Valuation Analysis
4.1 Price/Earnings Ratio
- NBTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NBTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as NBTX's earnings are expected to grow with 25.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.24%
EPS Next 3Y25.56%
5. NBTX Dividend Analysis
5.1 Amount
- No dividends for NBTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NBTX Fundamentals: All Metrics, Ratios and Statistics
NASDAQ:NBTX (5/1/2026, 8:00:01 PM)
35.12
+0.5 (+1.44%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength36.49
Industry Growth78
Earnings (Last)03-31 2026-03-31/bmo
Earnings (Next)05-19 2026-05-19
Inst Owners30.68%
Inst Owner Change0.01%
Ins Owners0.63%
Ins Owner ChangeN/A
Market Cap1.70B
Revenue(TTM)7.84M
Net Income(TTM)-23.96M
Analysts85
Price Target35.41 (0.83%)
Short Float %0.03%
Short Ratio0.18
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)29.87%
PT rev (3m)30.89%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)16.3%
EPS NY rev (3m)26.88%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.56%
Revenue NY rev (3m)-26.53%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 185.57 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.58
EYN/A
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)-0.82
FCFYN/A
OCF(TTM)-0.81
OCFYN/A
SpS0.19
BVpS-2.04
TBVpS-2.04
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.36% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-59.57%
ROA(5y)-64.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 36.52% | ||
| Cap/Sales | 6.96% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.09 | ||
| Quick Ratio | 1.09 | ||
| Altman-Z | -4.01 |
F-Score3
WACC7.87%
ROIC/WACCN/A
Cap/Depr(3y)37.04%
Cap/Depr(5y)26.45%
Cap/Sales(3y)5.13%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.2%
EPS Next Y-24.95%
EPS Next 2Y5.24%
EPS Next 3Y25.56%
EPS Next 5Y45.91%
Revenue 1Y (TTM)167.56%
Revenue growth 3YN/A
Revenue growth 5Y174.85%
Sales Q2Q%136.13%
Revenue Next Year9.99%
Revenue Next 2Y4.85%
Revenue Next 3Y37.36%
Revenue Next 5Y22.97%
EBIT growth 1Y52.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-506.53%
EBIT Next 3Y23.66%
EBIT Next 5Y124.47%
FCF growth 1Y-66.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-70.95%
OCF growth 3YN/A
OCF growth 5YN/A
NANOBIOTIX SA - ADR / NBTX Fundamental Analysis FAQ
What is the ChartMill fundamental rating of NANOBIOTIX SA - ADR (NBTX) stock?
ChartMill assigns a fundamental rating of 2 / 10 to NBTX.
Can you provide the valuation status for NANOBIOTIX SA - ADR?
ChartMill assigns a valuation rating of 1 / 10 to NANOBIOTIX SA - ADR (NBTX). This can be considered as Overvalued.
What is the profitability of NBTX stock?
NANOBIOTIX SA - ADR (NBTX) has a profitability rating of 0 / 10.
What is the expected EPS growth for NANOBIOTIX SA - ADR (NBTX) stock?
The Earnings per Share (EPS) of NANOBIOTIX SA - ADR (NBTX) is expected to decline by -24.95% in the next year.